{
  "docId": "019de515-df71-7068-a98d-cc2a99c8892d",
  "docSlug": "c88233ba648814c9f5b65afc1926df6d",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 11,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 20,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/9",
  "deckHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d",
  "deckJsonHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json",
  "deckAnchorHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.31,
        "w": 0.23,
        "x": 0.25,
        "y": 0.37
      },
      "kind": "chart",
      "text": "Reported protection against symptomatic COVID-19 (%) (Data from Phase 2/3 trials and real-world vaccine effectiveness studies) Geometric mean serum neutralizing titer (FRNT50)",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12397262-59e9-4e84-9e29-7757d27925b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.46,
        "w": 0.19,
        "x": 0.489,
        "y": 0.33
      },
      "kind": "list",
      "text": "AZD1222/WT (2nd dose + 14-28d)\nAZD1222/Alpha (2nd dose + 14-28d)\nAZD1222/Gamma (2nd dose + 14-28d)\nAZD1222/Delta (2nd dose + 14-28d)\nAZD1222/Omicron (2nd dose + 28d)\nBNT162b2/WT (2nd dose + 7-17d)\nBNT162b2/Alpha (2nd dose + 7-17d\nBNT162b2/Beta (2nd dose + 7-17d)\nBNT162b2/Gamma (2nd dose + 7-17d)\nBNT162b2/Delta (2nd dose + 7-17d)\nBNT162b2/Delta (2nd dose + 6M)\nBNT162b2/Delta (3rd dose + 28d)\nBNT162b2/Omi BA.1 (2nd dose + 6M)\nBNT162b2/WT (1st dose + 28d)\nadintrevimab/Omi BA.1/BA1.1 (d28)\nadintrevimab/Omi BA.1/BA1.1 (d60)\nadintrevimab/Omi BA.1/BA1.1 (d90)\nadintrevimab/Delta (d90)\nadintrevimab/Delta (d180)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d432ffc-d2a0-4979-b919-f5c73c9e5c46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.59,
        "x": 0.18,
        "y": 0.869
      },
      "kind": "paragraph",
      "text": "Strong scientific rationale for using surrogates of clinical efficacy in future trials, potentially accelerating clinical development path",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ac82f11-eb34-4777-90eb-56971abae26b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.46,
        "x": 0.02,
        "y": 0.973
      },
      "kind": "source-note",
      "text": "Source: Schmidt Sci Transl Med 2023; FRNT, focus reduction neutralization test",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d855116-62f1-412c-b5aa-86e0e6172a8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.053,
        "w": 0.605,
        "x": 0.17,
        "y": 0.227
      },
      "kind": "title",
      "text": "Serum neutralizing titers (either mAb or vaccine-induced) correlate with protection against symptomatic SARS-CoV-2 infection across multiple variants",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75d5cfd5-dba4-4d76-b035-efbc09d483cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.909,
        "x": 0.046,
        "y": 0.08
      },
      "kind": "title",
      "text": "SERUM VIRUS NEUTRALIZING ANTIBODY TITERS MAY PREDICT PROTECTION AGAINST SYMPTOMATIC COVID-19",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "228af1eb-8cac-4423-a4df-71d561ba30d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "c71d1650-7012-4826-8d41-2bb5b4993bcd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-10 propose Invivyd's solution and its potential to fulfill a large unmet need.",
      "position": 2,
      "confidence": 0.9,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "3b35d58f-2d99-44a5-b484-2bf12410ffb9",
      "evidence": "Slides 7-10 discuss market sizing, ongoing trials, and proposed solutions.",
      "position": 1,
      "objective": "How can Invivyd's VYD222 address the unmet need?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}